<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047510</url>
  </required_header>
  <id_info>
    <org_study_id>Chinese Academy of Sciences</org_study_id>
    <nct_id>NCT05047510</nct_id>
  </id_info>
  <brief_title>GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma</brief_title>
  <official_title>An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid&#xD;
      improve the surgical accuracy of hepatocellular carcinoma.&#xD;
&#xD;
      The main purposes of this study include:&#xD;
&#xD;
      ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel&#xD;
      NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore.&#xD;
&#xD;
      ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for&#xD;
      clinical application.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCC lesions</measure>
    <time_frame>During hepatocellular resection surgery.</time_frame>
    <description>Numbers of intraoperatively detected hepatocellular carcinoma lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anti-GPC3-IRDye800CW Intraoperative Fluorescence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-GPC3-IRDye800CW</intervention_name>
    <description>Drug Injection: Anti-GPC3-IRDye800CW</description>
    <arm_group_label>Anti-GPC3-IRDye800CW Intraoperative Fluorescence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have been diagnosed with hepatocellular carcinoma.&#xD;
&#xD;
          2. Planned to receive hepatectomy.&#xD;
&#xD;
          3. Liver function Child-Pugh A/B.&#xD;
&#xD;
          4. GPC-3 was validated highly expressed preoperatively.&#xD;
&#xD;
          5. Aged 18 to 75, and the expected lifetime is longer than 6 months.&#xD;
&#xD;
          6. Approved to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to IRDye800.&#xD;
&#xD;
          2. Enrolled in other trials in the past 3 months.&#xD;
&#xD;
          3. Another malignant tumor was found.&#xD;
&#xD;
          4. Undesirable function of heart, lung, kidney, or any other organs.&#xD;
&#xD;
          5. Unable to tolerate a hepatectomy.&#xD;
&#xD;
          6. The researchers considered inappropriate to be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zeyu Zhang, Ph.D.</last_name>
    <phone>86-18201082715</phone>
    <email>zhangzeyu@fingerpass.net.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 11, 2021</last_update_submitted>
  <last_update_submitted_qc>September 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Zeyu Zhang, PHD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

